Status:
RECRUITING
A Trial of RSC-1255 for Treatment of Patients With Advanced Malignancies
Lead Sponsor:
RasCal Therapeutics, Inc.
Conditions:
Advanced Malignant Solid Neoplasm
RAS Mutation
Eligibility:
All Genders
18+ years
Phase:
PHASE1
Brief Summary
RSC-101 is a Phase 1a/1b clinical trial of RSC-1255 in adult study participants with advanced solid tumor malignancies who are intolerant of existing therapies known to provide clinical benefit, have ...
Detailed Description
RSC-1255 is an orally bioavailable, small-molecule direct pan-mutant and wild-type RAS inhibitor. RSC-101 is a Phase 1a/1b, open-label, multi-center, non-randomized, Dose Escalation and Dose Expansion...
Eligibility Criteria
Inclusion
- Inclusion Criteria (Key Factors):
- Has pathologically confirmed advanced or metastatic malignancy characterized by one or more of the following:
- Participant is intolerant of existing therapy(ies) known to provide clinical benefit for their condition
- Malignancy is refractory to existing therapy(ies) known to potentially provide clinical benefit
- Malignancy has progressed on standard therapy
- Has evaluable or measurable tumor(s) in dose-escalation by standard radiological and/or laboratory assessments as applicable to their malignancy.
- Has adequate performance status (PS): Eastern Co-operative Oncology Group (ECOG).
- Is age ≥ 18 years.
- Exclusion Criteria (Key Factors):
- Participants receiving cancer therapy at the time of enrollment.
- Any clinically significant disease or condition affecting a major organ system.
- Significant cardiovascular disease or electrocardiogram (ECG) abnormalities.
- Known Gilbert's disease.
- Has had a previous (within 2 years) or has a current malignancy other than the target cancer.
Exclusion
Key Trial Info
Start Date :
March 3 2021
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
January 30 2027
Estimated Enrollment :
134 Patients enrolled
Trial Details
Trial ID
NCT04678648
Start Date
March 3 2021
End Date
January 30 2027
Last Update
May 8 2025
Active Locations (3)
Enter a location and click search to find clinical trials sorted by distance.
1
University of California, Los Angles (UCLA) Department of Medicine - Hematology/Oncology
Los Angeles, California, United States, 90404
2
Sarah Cannon, SCRI Oncology Partners - Health One
Denver, Colorado, United States, 80218
3
Sarah Cannon, SCRI Oncology Partners
Nashville, Tennessee, United States, 37203